Servier’s $1.5B bet on Edgewise drug fails five months in
Servier’s $1.6 billion Edgewise trial fails, ending its biggest bet on Becker muscular dystrophy.
Topic Intelligence Hub
32 verified news trends connected to this subject.
This hub groups 32 verified news trends connected to Biotech, spanning June 23, 2026 through November 4, 2026. Coverage totals 297 articles across 276 source signals, led by Business, Health, Science.
Servier’s $1.6 billion Edgewise trial fails, ending its biggest bet on Becker muscular dystrophy.
Ultragenyx slashes costs and reaffirms 2027 profit while Joby Aviation’s earnings lift its stock, spotlighting divergent paths in high‑growth sectors.
Moderna stock jumps on planned national cancer vaccine effort
Argenx's stock plummets after a surprise failure in a late-stage study of its autoimmune disease drug, but the company is still preparing for a pivotal run with a $2.2B treatment.
AstraZeneca pours over $1 billion into a new Cambridge R&D hub, saying it won’t need deals to grow past 2030.
Vaxcyte's stock soars 36% as pneumococcal vaccine shows promise against Pfizer and Merck.
Nvidia-backed Iambic Therapeutics' IPO filing surprises with disclosed clinic and dealmaking details amid a biotech IPO surge
Novartis’s $900 million BoomRay radioligand deal spotlights a China-origin, preclinical asset amid mounting competition in the biotech field
A September 14 FDA hearing pushes psychedelic drug standards to the forefront as veterans and the public demand faster access.
Bill Ackman's bold gamble on a mitochondrial eye transplant for his blind daughter thrust experimental vision therapy into the spotlight
The US government is investing heavily in on-demand RNA therapies, but the path to market is not straightforward.
Two positive Phase III results for an oral multiple sclerosis drug have pushed Novartis forward in a competitive pharmaceutical market.
Eli Lilly's $2.88 billion acquisition of Merida Biosciences is poised to reshape the autoimmune disease treatment landscape.
Nearly a dozen drug deals promise $600 billion in savings for American patients.
Congress pushes a China‑targeted biotech shield even as the sector rides a historic bull run.
A $1.5 billion China‑U.S. biotech pact puts American VCs and Haisco at the center of a new inflammatory‑disease platform.
Bristol Myers Squibb ends blood‑cancer deal, prompting Cellares to cut 100 jobs and reorganize.
Roche’s $2.5 billion pact for Hanmi’s muscle‑sparing obesity drug ignites expectations for a new weight‑loss breakthrough
A cancer vaccine breakthrough is stirring debate over profits and public health, as Moderna and Merck's stock prices surge.
A drug designed to mimic exercise has passed its first human test, sparking interest in the medical community.
Amylyx Pharmaceuticals' stock surges after a GLP-1 antagonist drug shows promise in a new application.
EyePoint Pharmaceuticals' stock plummets after a clinical trial setback, leaving investors reeling and analysts divided.
Scientists are racing to build AI-driven digital organisms to test drugs before human trials
The RK Mellon Foundation's $25M investment aims to transform Pittsburgh into a hub for rare disease therapies.
Boulevard Bio debuts with $65 million in funding to advance a pipeline of targeted antibody therapies focused on autoimmune disease.
Research indicates AI integration could deliver 82 times the return on investment in oncology clinical trials while reshaping the drug development market.
Alameda-based biotech Infinimmune has secured $75 million in Series A funding to advance its antibody pipeline for atopic dermatitis and inflammatory diseases.
LifeMine Therapeutics has secured a massive investment from tech giants Bill Gates and Jeff Bezos, despite conflicting reports on the amount raised.
Kindred Companion Sciences has unveiled the world's first beagles genetically edited via CRISPR to remove the protein responsible for triggering dog allergies.
An FDA advisory committee has voted 10-3 in favor of Replimune’s oncolytic immunotherapy for melanoma, marking a turning point for the twice-rejected treatment.
Celcuity stock fell by double digits despite securing its first FDA approval for a new breast cancer treatment.
Sangamo Therapeutics' bankruptcy filing and asset sale to Lilly and Astellas is making waves in the biotech industry.